iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

iBio Pharma (IBIO) news for Monday concerning an update about treatments for the novel coronavirus has IBIO stock soaring higher.
The post iBio Pharma News: Why IBIO Stock Is Surging 25% Today appeared first on InvestorPlace.

iBio Pharma News: Why IBIO Stock Is Surging 25% Today

ADMA Biologics

The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.

Why ADMA Biologics, iBio, and Kamada Are Jumping Today

IBIO stock has retreated sharply in recent weeks, and looks more attractive on the dip. But even cheaper, the stock looks like an avoid.

There Are Still Too Many Risks In iBio Stock

IBIO stock has continued its volatile swings, this time for the worse. Despite seemingly positive sentiment, it is too far behind to win.

IBIO Stock Is Likely Done in the Covid-19 Race

Don't waste money on iBio to bet on a Covid-19 vaccine winner. Since IBIO stock has risen so much, the probability of making money on this stock is extremely low.

Buying iBio As a Vaccine Winner Is a Waste of Money

IBIO stock has been acting like a potential COVID-19 vaccine producer, but it lacks contracts with leading providers and its own work remains at a pre-clinical stage. 
The post Investors Should View IBIO Stock Among Vaccine Wanna-be’s, Not Makers appeared first on InvestorPlace.

Investors Should View IBIO Stock Among Vaccine Wanna-be’s, Not Makers

Even with encouraging pre-clinical data released, iBio stock is still trading at a depressed price. Why not take advantage of that?

You Got Your Dip, Now Swoop in and Buy iBio

IBIO stock comes with all of the risks associated with penny stocks, making it a poor long-term play but worthwhile for traders willing to put some time into watching the stock's movement.
The post iBio Is a Risky Way to Make a Short-Term Profit appeared first on InvestorPlace.

iBio Is a Risky Way to Make a Short-Term Profit

There's promise in IBIO stock but potential investors need to study the biotech company carefully before placing their bets.
The post Dip Your Toes in iBio Stock, but Remember That Viability Is Still an Issue appeared first on InvestorPlace.

Dip Your Toes in iBio Stock, but Remember That Viability Is Still an Issue

IBIO stock is at a four-week low, so is now the time to invest in this biotech company searching for a Covid-19 vaccine?
The post With iBio at 4-Week Lows, Now May Be the Time to Buy appeared first on InvestorPlace.

With iBio at 4-Week Lows, Now May Be the Time to Buy

Aptinyx Inc

CymaBay Therapeutics

Evolus

Sientra

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Red-Hot Biotech and Medtech Stocks Under $10 With Massive Upside Potential

There's a much better way for investors to profit from a coronavirus vaccine than IBIO stock. 
The post Why Investors Shouldn’t Bet on iBio Stock Now appeared first on InvestorPlace.

Why Investors Shouldn’t Bet on iBio Stock Now

Although iBio lags others in the coronavirus vaccine race, this fact alone doesn’t necessarily mean that IBIO stock is hopelessly lost.
The post Read the Label Carefully Before Deciding on iBio appeared first on InvestorPlace.

Read the Label Carefully Before Deciding on iBio

IBIO stock is rewarding investors who bet on its unique approach to a Covid-19 vaccine. But as the field narrows, iBio needs to deliver more than a story.

Stay Away from iBio Until It Has More Than a Story

With iBio's FastPharming technology and its vaccines in the works, IBIO stock is well worth gambling on at  its current prices.
The post iBio Is One of the Top Pandemic Opportunities appeared first on InvestorPlace.

iBio Is One of the Top Pandemic Opportunities

- IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies - - IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies -

iBio Provides Update on IBIO-201 COVID-19 Vaccine Program

Vaxart

These two small-cap biotech stocks have intriguing COVID-19 vaccine candidates.

Better Coronavirus Stock: iBio vs. Vaxart

Too much speculation, and too weak fundamentals, makes IBIO stock a sell today for risk-adverse, disciplined investors.
The post iBio Stock Is a Highly Speculative Covid-19 Play That Isn’t Worth It appeared first on InvestorPlace.

iBio Stock Is a Highly Speculative Covid-19 Play That Isn’t Worth It

IBIO stock has more than double in price in recent weeks. Here’s why playing it safe makes sense.

Without a Covid-19 Vaccine, GERM Is a Much Safer Way to Play iBio Stock

Arcturus Therapeutics

The potential rewards are high. But so are the risks.

3 Small-Cap Coronavirus Stocks That Could Skyrocket

Digital Ally Inc

Foresight Autonomous Hlds

NovaBay Pharmaceuticals

Exela Technologies

XpresSpa Group

While penny stocks carry a high degree of risk, they could be a good place to look for value in today's market for investors that are willing to make short-term trades. These seven have potential catalysts on the horizon that make them worth considering.

7 Penny Stocks for the Valiant Investor

CHICAGO--(BUSINESS WIRE)--iBIO, the Illinois Biotechnology Innovation Organization, today announced the launch of Transform Illinois, http://ibio.org, its innovative new program to enhance pandemic preparedness and recovery, erase health equity barriers and continue to nurture the state’s life sciences community. iBIO created the Transform Illinois initiative as a natural evolution from its focus on the iBIO COVID-19 PPE Response Fund, developed through the organization’s role on the task force

iBIO Launches Transform Illinois Program

IBIO stock will go through peaks and valleys, but it's still a spec play lacking fundamental strength. Day traders should have fun, though.

A More Sustainable Business Model Doesn’t Make iBio Stock Less Risky

iBio stock has been surging over the past few trading sessions, as investors continue to bet on its success. Can it continue higher?

iBio Stock Has Tripled in a Few Weeks. Here’s What’s Next

That being said, it's too risky to go short as well. The party may soon be over for coroanvirus stocks.

News for iBio Stock (IBIO)